Natco Pharma shares surged on Wednesday, bouncing back from a three-day decline that followed a US FDA inspection of its API manufacturing facility in Manali, Chennai, conducted from November 17–21, 2025. The inspection flagged seven Form-483 observations, which the company termed procedural and manageable.